共 44 条
- [31] Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancerCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 547 - 558Li, ChunzeWang, BeiLu, DanJin, Y.Gao, YuyingMatsunaga, KiyoshiIgawa, YurikoNijem, IhsanLu, MichaelStrasak, AlexanderChernyukhin, NataliyaGirish, Sandhya
- [32] Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariatesCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 399 - 410Lu, DanGirish, SandhyaGao, YuyingWang, BeiYi, Joo-HeeGuardino, EllieSamant, MeghnaCobleigh, MelodyRimawi, MothaffarConte, PierfrancoJin, Jin Yan
- [33] Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors TreatmentONCOLOGIST, 2023, 28 (10): : e859 - e866Ji, ChenchenLi, FengYuan, YangZhang, HuiqiangBian, LiZhang, ShaohuaWang, TaoLi, JianbinJiang, Zefei
- [34] First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric CancerMOLECULAR CANCER THERAPEUTICS, 2021, 20 (08) : 1442 - 1453Pegram, Mark D.Hamilton, Erika P.Tan, Antoinette R.Storniolo, Anna MariaBalic, KemalRosenbaum, Anton, ILiang, MeinaHe, PengMarshall, ShannonScheuber, AnitaDas, MayukhPatel, Manish R.
- [35] A PHASE 2 STUDY OF THE HER2 ANTIBODY-DRUG CONJUGATE TRASTUZUMAB-DM1 (T-DM1) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH TRASTUZUMAB, LAPATINIB, AND CHEMOTHERAPYANNALS OF ONCOLOGY, 2010, 21 : 97 - 97Krop, I.LoRusso, P.Miller, K. D.Modi, S.Yardley, D.Rodriguez, G.Lu, M.Burington, B.Agresta, S.Rugo, H.
- [36] Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed TherapyJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) : 398 - 405Burris, Howard A., IIIRugo, Hope S.Vukelja, Svetislava J.Vogel, Charles L.Borson, Rachel A.Limentani, StevenTan-Chiu, ElizabethKrop, Ian E.Michaelson, Richard A.Girish, SandhyaAmler, LukasZheng, MaoxiaChu, Yu-WayeKlencke, BarbaraO'Shaughnessy, Joyce A.
- [37] Population Pharmacokinetics of Trastuzumab-DM1, a First-in-Class HER2 Antibody-Drug Conjugate Given Every 3 Weeks (q3w) and Weekly (qw) to Patients with HER2-Positive Metastatic Breast Cancer (MBC)CANCER RESEARCH, 2009, 69 (24) : 798S - 799SLoRusso, P.Girish, S.Burris, H. A.Beeram, M.Vukelja, S.Modi, S.Yi, J-HWang, B.Saad, O.Gupta, M.
- [39] BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 studyCANCER RESEARCH, 2024, 84 (09)Song, ErweiYao, HeruiSun, MeiliZong, HongLin, RongboZou, WenDing, MuranYu, JingXiao, SaWang, HongweiZhu, HaiOlivo, MartinZhu, Yi
- [40] Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Lu, Janice M.Kalinsky, KevinTripathy, DebuSledge, George W.Gradishar, William JohnO'Regan, RuthO'Shaughnessy, JoyceModi, ShanuPark, HaeseongMcCartney, AmeliaFrentzas, SophiaShannon, Catherine M.Eek, Richard WilhelmMartin, MiguelCurigliano, GiuseppeJerusalem, Guy Heinrich MariaHuang, Chiun-ShengPress, Michael F.Tolaney, Sara M.Hurvitz, Sara A.